These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31915365)

  • 1. Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma.
    Schieferdecker A; Hörber S; Ums M; Besemer B; Bokemeyer C; Peter A; Weisel K
    Blood Cancer J; 2020 Jan; 10(1):2. PubMed ID: 31915365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.
    Caillon H; Avet-Loiseau H; Attal M; Moreau P; Decaux O; Dejoie T
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e228-e237. PubMed ID: 30799237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
    Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
    Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory.
    Caponi L; Romiti N; Koni E; Fiore AD; Paolicchi A; Franzini M
    Crit Rev Clin Lab Sci; 2020 Mar; 57(2):73-85. PubMed ID: 31612753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implication by differential analytical performances of serum free light chain quantitation analysis using fully automated analyzers.
    Yun SY; Rim JH; Park H; Kang H; Lee SG; Lim JB
    Clin Chem Lab Med; 2023 Jun; 61(7):1288-1299. PubMed ID: 37015073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Freelite and N-Latex serum free light chain assays: a critical review.
    Daves M; Piccin A; Roccaforte V; Lippi G
    Biochem Med (Zagreb); 2021 Oct; 31(3):030701. PubMed ID: 34393594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Two Serum Free Light Chain Detection Systems in the Diagnosis of Multiple Myeloma].
    Zhu GQ; Fu X; Ren YS; Wang YS; Wang SL; Wang LC; Lin J; An G
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1209-1215. PubMed ID: 34362504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
    Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Method comparison of three serum free light chain assays on the Roche Cobas 6000 c501 chemistry analyzer.
    Augustijn D; Jacobs JFM; Russcher H
    Clin Chem Lab Med; 2022 Feb; 60(3):379-385. PubMed ID: 34969184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Freelite serum free light chain (SFLC) assay with serum and urine electrophoresis/immunofixation and the N Latex FLC assay.
    Sasson SC; McGill K; Wienholt L; Carr A; Brown DA; Kelleher AD; Breit SN; Sewell WA
    Pathology; 2015 Oct; 47(6):564-9. PubMed ID: 26352111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of serum free light chains measurement in patients with multiple myeloma: comparative analysis of two different tests.
    Kubicki T; Dytfeld D; Baszczuk A; Wysocka E; Komarnicki M; Lewandowski K
    Postepy Hig Med Dosw (Online); 2017 Jan; 71(0):40-46. PubMed ID: 28181910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy.
    Kim HS; Kim HS; Shin KS; Song W; Kim HJ; Kim HS; Park MJ
    Biomed Res Int; 2014; 2014():647238. PubMed ID: 24971342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical specificity of two assays for immunoglobulin kappa and lambda free light chains.
    Farnsworth CW; Roemmich B; Spears GM; Murray DL; Dispenzieri A; Willrich MAV
    Clin Chem Lab Med; 2024 Apr; 62(5):929-938. PubMed ID: 38044587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.
    Palladini G; Jaccard A; Milani P; Lavergne D; Foli A; Bender S; Lavatelli F; Bosoni T; Valentini V; Pirolini L; Ferraro G; Basset M; Russo F; Nuvolone M; Albertini R; Cogne M; Merlini G
    Clin Chem Lab Med; 2017 Oct; 55(11):1734-1743. PubMed ID: 28343171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the new Sebia free light chain assay using the AP22 ELITE instrument.
    Lutteri L; Aldenhoff MC; Cavalier E
    Clin Chim Acta; 2018 Dec; 487():161-167. PubMed ID: 30243748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum free light chain reference intervals in an Optilite and their influence on clinical guidelines.
    Morales-García LJ; Pacheco-Delgado MS
    Clin Biochem; 2021 Jun; 92():54-60. PubMed ID: 33662349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
    Larsen JT; Kumar SK; Dispenzieri A; Kyle RA; Katzmann JA; Rajkumar SV
    Leukemia; 2013 Apr; 27(4):941-6. PubMed ID: 23183428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum free light chains for diagnosis and follow-up of multiple myeloma].
    Jung S; Kim M; Lim J; Kim Y; Han K; Min CK; Min WS
    Korean J Lab Med; 2008 Jun; 28(3):169-73. PubMed ID: 18594166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.